Success Metrics

Clinical Success Rate
55.6%

Based on 5 completed trials

Completion Rate
56%(5/9)
Active Trials
1(9%)
Results Posted
180%(9 trials)
Terminated
4(36%)

Phase Distribution

Ph phase_3
3
27%
Ph phase_2
8
73%

Phase Distribution

0

Early Stage

8

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
8(72.7%)
Phase 3Large-scale testing
3(27.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

5 of 10 finished

Non-Completion Rate

50.0%

5 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(5)
Terminated(5)

Detailed Status

Completed5
Terminated4
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
55.6%
Most Advanced
Phase 3

Trials by Phase

Phase 28 (72.7%)
Phase 33 (27.3%)

Trials by Status

withdrawn19%
completed545%
recruiting19%
terminated436%

Recent Activity

1 active trials
Showing 5 of 11
recruitingphase_2

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

NCT05835466
terminatedphase_3

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

NCT05254990
terminatedphase_2

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

NCT03031470
completedphase_3

Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.

NCT04878055
withdrawnphase_2

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

NCT05212701
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05835466Phase 2

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Recruiting
NCT05254990Phase 3

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
NCT03031470Phase 2

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

Terminated
NCT04878055Phase 3

Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.

Completed
NCT05212701Phase 2

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Withdrawn
NCT04794803Phase 2

Reparixin in COVID-19 Pneumonia - Efficacy and Safety

Terminated
NCT01817959Phase 3

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

Completed
NCT01967888Phase 2

Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Completed
NCT02370238Phase 2

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

Completed
NCT01861054Phase 2

Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

Terminated
NCT01220856Phase 2

Reparixin in Pancreatic Islet Transplantation

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11